HOME
CAREER NETWORK
NEWS
HOTBEDS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
RESEARCH STORE
ABOUT US
NEWSLETTERS Free Newsletters Archive My Subscriptions NEWS News by Subject News by Disease News by Date PLoS Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Most Recent Jobs Browse Biotech Jobs Search Jobs Post Resume Career Fairs Career Resources For Employers HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia DIVERSITY INVESTOR Market Summary News IPOs PROFILES Company Profiles START UPS Companies Events INTELLIGENCE Research Store INDUSTRY EVENTS Biotech Events Post an Event RESOURCES Real Estate Business Opportunities
The decision to discontinue our lawsuit seeking to extend the director nomination deadline was the result of discussions I had with Daniel Bradbury, Amylin's chief executive officer, that we agreed would not be publicly disclosed.
Mr. Icahn reiterated that he continues to strongly believe that the company should be sold at this time.
SOURCE Carl C. Icahn